| Bioactivity | KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses[1][2]. | ||||||||||||
| Invitro | KIN1408 has the potency to drive IRF3 activation to induce innate immune gene (MDA5, RIG-1, Mx1, IRF7, and IFIT1 in THP-1 cells) expression and that concomitantly suppress dengue virus2 RNA to levels. KIN1408 also exhibits activity against HCV, influenza A, Ebola, Nipah, and Lassa viruses[1][2]. | ||||||||||||
| Name | KIN1408 | ||||||||||||
| CAS | 1903800-11-2 | ||||||||||||
| Formula | C25H19F2N3O3S | ||||||||||||
| Molar Mass | 479.50 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Green RR, et al. Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway. Genom Data. 2016 Feb 1;7:290-2. [2]. Sowmya Pattabhi, et al. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol. 2015 Dec 16;90(5):2372-87. |
KIN1408
CAS: 1903800-11-2 F: C25H19F2N3O3S W: 479.50
KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.